NAVB Navidea Biopharmaceuticals Dashboard

Navidea Biopharmaceuticals, Inc. engages in the development and commercialization of precision immunodiagnostic agents and immunotherapeutic. It operates through the following segments: Diagnostics, Therapeutics, and Corporate. The company was founded in 1983 and is headquartered in Dublin, OH.

Company profile

Ticker

NAVB

Exchange

NYSE

Website

www.navidea.com/

CEO

Jed Latkin

Incorporated

Delaware

Location

Ohio

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

In Vitro & In Vivo Diagnostic Substances

Idexx Laboratories • Myriad Genetics • Lantheus • Quidel • Neogen • Meridian Bioscience • Celldex Therapeutics • Oxford Immunotec Global • Achieve Life Sciences • Intellia Therapeutics ...

Former names

NEOPROBE CORP

SEC CIK

0000810509

Corporate docs

Articles of Incorporation & Bylaws

IRS number

311080091

NAVB stock data

S&P 500

1M 1Y 2Y 5Y

News

Pro users get this 30m faster

Navidea Bio World Intellectual Property Organization PatentScope Listing For Co.'s ' COMPOSITIONS AND RELATED METHODS FOR BLOCKING OFF-TARGET LOCALIZATION OF MANNOSYLATED DEXTRANS AND OTHER CD206 LIGANDS'

8 Apr 21

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021067479&tab=PCTDESCRIPTION

Navidea Biopharmaceutical Q4 EPS $(0.11) Beats $(0.12) Estimate, Sales $219.25K Miss $600.00K Estimate

24 Mar 21

Navidea Biopharmaceutical (AMEX:NAVB) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.12) by 8.33 percent. This is a 26.67 percent increase over losses of $(0.15) per share

The Daily Biotech Pulse: Dynavax-Clover Start Phase 2/3 Vaccine Study. BrainStorm Reports Positive MS Readout, NeoGenomics Goes Shopping

24 Mar 21

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 23)

Earnings Scheduled For March 24, 2021

24 Mar 21

FDA Decisions For Pfizer, Eli Lilly And Bluebird Bio, Bristol-Meyers Squibb, Plus New Data And Earnings

20 Mar 21

Press releases

Pro users get this 30m faster

Navidea Biopharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results

24 Mar 21

Conference Call to be held Wednesday, March 24, 2021 at 5:00 pm EDT Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents

Navidea Biopharmaceuticals, Inc. to Host Earnings Call

24 Mar 21

NEW YORK, NY / ACCESSWIRE / March 24, 2021 / Navidea Biopharmaceuticals, Inc. (AMEX:NAVB) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on March 24, 2021 at 5:00 PM

Navidea Biopharmaceuticals to Host Fourth Quarter 2020 Earnings Conference Call and Corporate Update

17 Mar 21

Conference Call to be Held on Wednesday, March 24, 2021 at 5:00 p.m. (EDT) Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic

Navidea Biopharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Virtual Conference

2 Mar 21

Navidea Biopharmaceuticals Announces $5 Million Private Placement with Existing Investor

2 Mar 21

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

26 Mar 21

13 Apr 21

31 Dec 21

Financial summary

Financial statements Chart NAVB financial data

Quarter (USD)	Dec 20	Sep 20	Jun 20	Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 20	Dec 19	Dec 18	Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated)	Burn method: Change in cash		Burn method: Operating income/loss		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	2.67M	2.67M	2.67M	2.67M	2.67M	2.67M
Cash burn (monthly)	350.79K	(positive/no burn)	941.04K	894.72K	852.29K	681.15K
Cash used (since last report)	1.21M	n/a	3.25M	3.09M	2.95M	2.35M
Cash remaining	1.46M	n/a	-581.36K	-421.3K	-274.66K	316.72K
Runway (months of cash)	4.2	n/a	-0.6	-0.5	-0.3	0.5

Beta Read what these cash burn values mean

Recent insider trades

NAVB insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
29 Mar 21	Malcolm G Witter	Common Stock	Buy	Aquire P	No	No	2.07	21,500	44.51K	47,000
3 Mar 21	Malcolm G Witter	Common Stock	Buy	Aquire P	No	No	2.31	15,000	34.65K	25,500
2 Mar 21	Scott John K Jr.	Series E Redeemable Convertible Preferred Stock Common Stock	Buy	Aquire P	No	No	100	50,000	5M	50,000
15 Feb 21	Latkin Jed	Stock Option Common Stock	Grant	Aquire A	No	No	0.001	100,000	100	100,000
15 Feb 21	Joel H. Kaufman	Stock Option Common Stock	Grant	Aquire A	No	No	0.001	25,000	25	25,000

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q4 2020

NAVB institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders	Current	Prev Q	Change
Total holders	0	0
Opened positions	0	0
Closed positions	0	0
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	0	0
Total shares	0	0
Total puts	0	0
Total calls	0	0
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change

Largest transactions	Shares	Bought/sold	Change

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: accredited, Actinium, Adaptimmune, adjudicate, aim, alpha, anticancer, article, ASR, aTyr, banker, BCF, Bellicum, Brexit, British, Calithera, CDC, Checkpoint, ChemoCentryx, Cidara, comment, CytomX, dba, Dean, devastating, dissolution, Distinguishing, docketed, Draximage, ELDA, empowering, EPS, EULAR, factor, Fate, forgiven, France, GeoVax, Germany, Goldman, hard, Heron, honesty, Indenture, inspired, Irish, Joel, Jubilant, Judge, Kaufman, Kibble, Kingdom, labor, Latin, Lineage, Magistrate, Malcolm, mandatorily, Marker, Mastiff, memorandum, mezzanine, mitigate, MOU, multiplying, Neoleukin, Neuroscience, ninety, Northwest, Northwestern, Official, OncoSec, passion, payroll, PDL, perfected, persistence, Phio, PPP, Prentice, proinflammatory, Prothena, Radiopharma, reproducible, SBA, Selecta, show, signal, Stanford, strive, synergized, syngeneic, tenant, thrive, timeline, TNF, TRA, UK, unconditional, unexpectedly, USI, virtual, webcast, Wharton, Witter, workplace, worse, Zealand, Ziopharm

Removed: AA, accessible, AD, affinity, affirmative, Affordable, alternatively, Alzheimer, amyloid, announcement, applying, attributed, autoimmune, bore, brain, budgetary, chosen, classically, cognitive, collateralized, comparator, compounding, CRC, CROI, cured, deadline, declined, dementia, departure, deplete, diagnosing, directionally, discontinued, discounted, diversion, doubt, dramatic, employing, exclusively, exempt, extinguishment, fluid, frozen, hierarchy, hinder, homeland, hurt, identical, incurrence, ineligible, infrequently, instituted, invoke, juncture, labeled, leverage, liver, living, lowest, MCI, metastatic, Miami, microgram, mild, minimal, modulate, mortality, NCI, necessarily, neurological, neurology, Obama, observable, overhaul, paying, peripheral, phenotype, possession, prepayment, pressure, quantify, quantitative, quoted, RDD, realignment, recording, reducing, relation, rental, retrospective, risen, safely, shift, simultaneously, slowly, specificity, stayed, stopped, studied, sublicensed, suggest, Summit, suspected, top, topical, transparency, treating, unadjusted, unavailable, undertaken, unexpired, unobservable, unrealized, unrestricted

From filing 10-K 2020 FY